Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 18/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10144278 | 0.85 | GPR35 (0.73) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL10186088 | 0.79 | GPR35 (0.66) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL2176204 | 0.79 | GPR35 (0.65) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL10175272 | 0.78 | GPR35 (0.63) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL406991 | 0.77 | GPR35 (0.62) | GPR35 | |
| SCHEMBL2176207 | 0.76 | GPR35 (0.61) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL321098 | 0.75 | GPR35 (0.60) | GPR35PKM | |
| SCHEMBL1851331 | 0.75 | GPR35 (0.60) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL10186093 | 0.75 | GPR35 (0.60) | GPR35PKMNPSR1RXFP1 | |
| SCHEMBL15342922 | 0.74 | GPR35 (0.67) | GPR35PKMNPSR1RXFP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | PROMETHEUS BIOSCIENCES INC (US) | 2025-11-06 | — | — | US | disclosed |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-08-19 | — | — | US | disclosed |
| US-20250230505-A1 | METHODS OF TREATING REFRACTORY INFLAMMATORY DISEASE USING TRANSCRIPTOMIC AND GENETIC RISK SIGNATURES | CEDARS-SINAI MEDICAL CENTER | 2025-07-17 | — | — | US | disclosed |
| US-12264368-B2 | Methods of treating refractory inflammatory disease using transcriptomic and genetic risk signatures | CEDARS-SINAI MEDICAL CENTER (US) | 2025-04-01 | — | — | US | disclosed |
| US-12215147-B2 | Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody | PROMETHEUS BIOSCIENCES, INC. (US) | 2025-02-04 | — | — | US | disclosed |
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-08-31 | — | — | US | disclosed |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | PROMETHEUS BIOSCIENCES, INC. | 2023-01-19 | — | — | US | disclosed |
| EP-3969621-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | Prometheus Biosciences, Inc. (US) | 2022-03-23 | — | — | EP | disclosed |
| US-8575354-B1 | Fused thiophenes and methods for making and using same | CORNING INCORPORATED (US) | 2013-11-05 | — | — | US | disclosed |
| US-20130281707-A1 | FUSED THIOPHENES AND METHODS FOR MAKING AND USING SAME | CORNING INC (US) | 2013-10-24 | — | — | US | disclosed |
| EP-2595975-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | Corning Incorporated (US) | 2013-05-29 | — | — | EP | disclosed |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | CORNING INCORPORATED | 2012-11-22 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED | 2012-01-26 | — | — | US | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2012012278-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | CORNING INCORPORATED (US) | 2012-01-26 | — | — | WO | disclosed |
| WO-2011081971-A2 | EGFR/VEGFR DUAL MODULATORS AND METHODS OF USING | CORNING INCORPORATED (US) | 2011-07-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230272061-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | GPR35 4446/4885PKM 4866/4885NPSR1 4715/4885 |
| US-20120022116-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF PATHOLOGICAL CONDITION(S) RELATED TO GPR35 AND/OR GPR35-HERG COMPLEX | GPR35, GPR65, GPR68 | GPR35 1/4885PKM 1825/4885NPSR1 410/4885 |
| US-20230018729-A1 | TL1A PATIENT SELECTION METHODS, SYSTEMS, AND DEVICES | TLL1, TLN1, TSG101 | GPR35 4446/4885PKM 4866/4885NPSR1 4715/4885 |
| US-20250340627-A1 | METHODS OF SELECTING, BASED ON POLYMORPHISMS, AN INFLAMMATORY BOWEL DISEASE SUBJECT FOR TREATMENT WITH AN ANTI-TL1A ANTIBODY | TLL1, TSG101, DNASE1L3 | GPR35 2436/4885PKM 4880/4885NPSR1 4435/4885 |
| US-12391752-B2 | Methods of enriching or amplifying nucleic acids in a sample from a patient with inflammatory bowel disease | DNASE1L3, TLL1, RNASE1 | GPR35 3434/4885PKM 4860/4885NPSR1 4658/4885 |
| US-20120295965-A1 | FUSED THIOPHENES AS DUAL INHIBITORS OF EGFR/VEGFR AND THEIR USE IN THE TREATMENT OF CANCER | EGFR, ERBB2, KDR | GPR35 1127/4885PKM 4079/4885NPSR1 2283/4885 |
| US-12215147-B2 | Methods of selecting, based on polymorphisms, an inflammatory bowel disease subject for treatment with an anti-TL1A antibody | TLL1, TSG101, DNASE1L3 | GPR35 2436/4885PKM 4880/4885NPSR1 4435/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.